medigraphic.com
Sociedad Mexicana de Cirujanos Torácicos Genrales S.C.

2026, Number 2

<< Back Next >>

Rev Mex Cir Torac Gen 2026; 4 (2)

Surgical treatment of non-small cell lung cancer in clinical stage IIIA (N2)

Waldo-Hernández LI, Armas-Zárate FJ, Iñiguez-García MA

Language: Spanish
References: 10
Page: 58-61
PDF size: 1288.23 Kb.


ABSTRACT

Non-small cell lung cancer (NSCLC) continues to be one of the most advanced pathological entities in terms of medical and surgical treatment, with focus on both detection by screening and surgical management in locally advanced clinical stages, which were previously destined to receive only medical treatment thanks to the advent of targeted therapies and immunotherapy. We present the case of a 69-year-old male patient with EGFR-positive lung adenocarcinoma in clinical stage IIIA due to single positive N2 (7) who received neoadjuvant targeted therapy and subsequent surgical resection and who is currently in remission of the disease.


REFERENCES

  1. Pirlog R, Chiroi P, Rusu I, Jurj AM, Budisan L, Pop-Bica C et al. Cellularand molecular profiling of tumor microenvironment and early-stage lungcancer. Int J Mol Sci. 2022;23(10):5346. doi: 10.3390/ijms23105346.

  2. Hardenberg MC, Patel B, Matthews C, Califano R, Garcia Campelo R,Grohe C et al. The value of disease-free survival (DFS) and osimertinibin adjuvant non-small-cell lung cancer (NSCLC): an internationalDelphi consensus report. ESMO Open. 2022;7(5):100572. doi:10.1016/j.esmoop.2022.100572.

  3. Janik M, Lucenic M, Tarabova K, Juhos P, Laucek P, Siska D. Uniportalthoracoscopic sublobar anatomical resections for small pulmonarynodules. Bratisl Lek Listy. 2022;123(7):533-538. doi: 10.4149/BLL_2022_093.

  4. Zhong W, Yang X, Yan H, Zhang X, Su J, Chen Z et al. Phase II studyof biomarker-guided neoadjuvant treatment strategy for IIIA-N2 nonsmallcell lung cancer based on epidermal growth factor receptormutation status. J Hematol Oncol. 2015;8:54. doi: 10.1186/s13045-015-0151-3.

  5. Lopez-Chavez A, Thomas A, Evbuomwan MO, Xi L, Chun G,Vidaurre T t al. EGFR mutations in Latinos from the United Statesand Latin America. J Glob Oncol. 2016;2(5):259-267. doi: 10.1200/JGO.2015.002105.

  6. Hernández-Pedro N, Soca-Chafre G, Alaez-Versón C, Carrillo-SánchezK, Avilés-Salas A, Vergara E et al. Mutational profile by targetednext generation sequencing of non-small cell lung cancer in theMexican population. Salud Pública Méx. 2019;61(3):308-317. doi:10.21149/10113.

  7. Cansouline X, Lipan B, Sizaret D, Tallet A, Vandier C, Carmier D et al.EGFR-mutant non-small-cell lung cancer at surgical stages: what is theplace for tyrosine kinase inhibitors? Cancers (Basel). 2022;14(9):2257.doi: 10.3390/cancers14092257.

  8. Alves Pinto I, de Oliveira Cavagna R, Virginio da Silva AL, Dias JM,Santana IV, Souza LC et al. EGFR mutations and PD-L1 expression inearly-stage non-small cell lung cancer: a real-world data from a singlecenter in Brazil. Oncologist. 2022;27(11):e899-e907. doi: 10.1093/oncolo/oyac167.

  9. Ehrenstein V, Eriksen K, Taylor A, Servidio L, Jakobsen E. Characteristicsand overall survival of patients with early-stage non-small cell lungcancer: A cohort study in Denmark. Cancer Med. 2023;12(1):30-37.doi: 10.1002/cam4.4946.

  10. Gallina FT, Bertolaccini L, Forcella D, Mohamed S, Ceddia S, Melis E etal. Analysis of molecular biomarkers in resected early-stage non-smallcells lung cancer: a narrative review. Cancers (Basel). 2022;14(8):1949.doi: 10.3390/cancers14081949.




2020     |     www.medigraphic.com